Modality
Peptide
MOA
MALT1i
Target
Aβ
Pathway
RNA Splicing
SCLCIgANRCC
Development Pipeline
Preclinical
~Dec 2014
→ ~Mar 2016
Phase 1
~Jun 2016
→ ~Sep 2017
Phase 2
Dec 2017
→ Dec 2030
Phase 2Current
NCT07094852
2,780 pts·IgAN
2017-12→2025-07·Not yet recruiting
NCT07318702
654 pts·IgAN
2022-05→2030-12·Not yet recruiting
3,434 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-218mo agoPh2 Data· IgAN
2030-12-144.7y awayPh2 Data· IgAN
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Not yet…
P2
Not yet…
Catalysts
Ph2 Data
2025-07-21 · 8mo ago
IgAN
Ph2 Data
2030-12-14 · 4.7y away
IgAN
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07094852 | Phase 2 | IgAN | Not yet recr... | 2780 | EDSS |
| NCT07318702 | Phase 2 | IgAN | Not yet recr... | 654 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ |